RARITAN, NJ (August 22, 2016) – Janssen Pharmaceuticals, Inc., today announced that 25 abstracts have been accepted for presentation by Janssen and its development partner, Bayer, at the ESC Congress 2016, taking place August 27-31 in Rome, Italy. New real-world evidence from the EXPLORER research program, including latest findings from the REVISIT-US study, will address how XARELTO® (rivaroxaban), a non-vitamin K antagonist oral anticoagulant (NOAC), is performing in routine clinical practice. Also, the companies will unveil the design of the GALILEO trial, which seeks to address blood clot prevention for patients following successful transcatheter aortic valve replacement (TAVR).
http://www.jnj.com/news/all/Janssen-Announces-25-Presentations-at-Upcoming-ESC-Congress-2016-Including-New-Clinical-and-Real-World-Research-on-XARELTO-and-Latest-Findings-from-REVISIT-US
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.